

**CBE ID**

2417

**Title**

Risk Assessment/Treatment After Fracture

**Project**

Primary Care and Chronic Illness

**Endorsement Status**

Endorsement Removed

**Is Under Review**

No

**Previous Endorsement Cycle**

Fall 2017

**Removal Date**

Sun, 10/29/2017 - 20:00

**Initial Endorsement**

Tue, 09/02/2014 - 13:37

**Steward**

The Joint Commission

**1.0 New or Maintenance**

Maintenance

**1.1 Measure Structure**

Single Measure

**1.3 Electronic Clinical Quality Measure (eCQM)**

No

**1.6 Measure Description**

Patients age 50 or over with a fragility fracture who have either a dual-energy X-Ray absorptiometry (DXA) scan ordered or performed, or a prescription for FDA-approved pharmacotherapy for osteoporosis, or who are seen by or linked to a fracture liaison service prior to discharge from inpatient status,. If DXA is not available and documented as such, then any other specified fracture risk assessment method may be ordered or performed.

**1.7 Measure Type**

Process

---

## 1.8 Level of Analysis

Facility

## 1.9 Care Setting

Inpatient/Hospital

## 1.14 Numerator

Patients who had either a DXA scan ordered or performed, OR a prescription for FDA-approved pharmacotherapy for osteoporosis treatment, OR those who were seen by, contacted by, or linked to a fracture liaison service prior to discharge OR had other fracture risk assessment method ordered or performed if DXA is not available.

## 1.15 Denominator

Patients age 50 and over discharged from inpatient status with an ICD-10-CM Principal or Other Diagnosis Code of selected fractures as defined in Table 3.1 Vertebral Fracture, Table 4.1 Hip Fracture, or Table 5.1 Other Fracture,

## 1.20 Types of Data Sources

Other, Paper Patient Medical Records

## 6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

## Exclusions

- Age less than 50 years
- “Comfort Measures Only” documented
- Enrollment in a clinical trial pertaining to osteoporosis
- On FDA-Approved pharmacotherapy for osteoporosis treatment as defined in Table 1.1 prior to the fracture date
- Bone Mineral density test documented in the 12 months prior to the fracture
- Expired

See attached Excel file for definitions

## Planned Use

Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

## Risk Adjustment

No risk adjustment or risk stratification

## Target Population

Elderly, Populations at Risk

## Steward Organization

The Joint Commission

**Steward POC email**

[jalban@jointcommission.org](mailto:jalban@jointcommission.org)